Tower Research Capital LLC (Trc) Gain Therapeutics, Inc. Transaction History
Tower Research Capital LLC (Trc)
- $3.53 Billion
- Q2 2025
A detailed history of Tower Research Capital LLC (Trc) transactions in Gain Therapeutics, Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 945 shares of GANX stock, worth $1,445. This represents 0.0% of its overall portfolio holdings.
Number of Shares
945
Previous 2,432
61.14%
Holding current value
$1,445
Previous $4,000
75.0%
% of portfolio
0.0%
Previous 0.0%
Shares
16 transactions
Others Institutions Holding GANX
# of Institutions
39Shares Held
4.47MCall Options Held
37.9KPut Options Held
0-
Jones Financial Companies Lllp677KShares$1.04 Million0.0% of portfolio
-
David Einhorn Greenlight Capital Inc | New York, Ny588KShares$900,2670.1% of portfolio
-
Dme Capital Management, LP New York, NY566KShares$866,1780.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA534KShares$817,5580.0% of portfolio
-
Geode Capital Management, LLC Boston, MA290KShares$444,4060.0% of portfolio
About Gain Therapeutics, Inc.
- Ticker GANX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 11,883,400
- Market Cap $18.2M
- Description
- Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietar...